SEATTLE & VANCOUVER, British Columbia–(BUSINESS WIRE)–Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) and SōRSE Technology Corporation (“SōRSE”) have entered into a Collaborative Research Agreement to advance Pascal’s PAS-393 into clinical testing. Pascal and SōRSE will share their respective technologies to test the cannabinoid PAS-393 in human volunteers, enabling testing of cancer patients treated with checkpoint inhibitors. As initially announced last March, this partnership leverages SōRS